We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Use of Molecular Assays for HIAs Growing Rapidly

By LabMedica International staff writers
Posted on 07 Oct 2010
Molecular tests that can quickly identify hospital- acquired infections (HIAs) are rapidly becoming more popular. More...


The most serious HAIs include methicillin resistant Staphylococcus aureus (MRSA), Clostridium difficile, which causes an intestinal infection), Vancomycin-resistant Enterococcus, linked with intestinal, skin and blood infections, and drug-resistant Acinetobacter, which can cause pneumonia, skin, and blood infections.

There are several approaches to HAI detection. On the conservative and least expensive side are chromogenic growth media that permit the selective growth of MRSA bacteria and produce a colored colony that is easily recognizable. On the more expensive side, there has been an explosion of user-friendly molecular assays that are widely accepted.

Kalorama Information (Rockville, MD, USA), a healthcare market research publisher, has reported that molecular tests that can quickly identify patients for isolation and treatment are being utilized despite their higher cost. Kalorama forecasts that revenues for molecular tests that detect HAIs will grow at 25% per year for the next five years.

"They are growing at four times the rate of the average IVD products,” said Shara Rosen, senior diagnostic analyst for Kalorama Information and the author of the report. "HAIs are a huge problem and this is an opportunity for the most logical tests to treat them.”

The advantage of these molecular tests is that they can provide highly sensitive rapid turnaround results. Cepheid (Sunnyvale, CA, USA), Becton Dickinson (BD; Franklin Lakes, CA, USA), and Seegene (Seoul, Korea) are among the companies with products used to test for HAIs.

The US Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA) estimates that HAIs affect nearly 2 million Americans annually, resulting in 90,000 deaths and up to US $6.5 billion in extra costs.

Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services.

Related Links:
Cepheid
Becton Dickinson
Seegene
Kalorama Information
U.S. Centers for Disease Control and Prevention



Gold Member
Automatic Hematology Analyzer
CF9600
Online QC Software
Acusera 24•7
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
New
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: For decades, laboratories have adjusted total calcium for albumin, but growing evidence shows these corrections often perform poorly and may cause harm (image credit: iStock)

International Experts Recommend Ending Routine 'Corrected' Calcium Reporting

Interpreting serum calcium can be clinically challenging when albumin levels vary, especially in patients with chronic illness or kidney disease. For decades, laboratories have used formulas to adjust... Read more

Molecular Diagnostics

view channel
Image: The integrated multi-omics approach may help identify bladder cancer patients likely to respond to BCG and those needing alternative or intensified treatment (image credit: iStock)

Multi-Omics Profiling Helps Predict BCG Response and Recurrence in Bladder Cancer

High-risk non–muscle-invasive bladder cancer frequently recurs after therapy, with about 30% of patients relapsing and roughly 10% dying within two years despite tumor resection, surveillance, and Bacillus... Read more

Microbiology

view channel
Image: The findings suggest that people with mpox can transmit the virus even without clinical symptoms (image credit: Adobe Stock)

Study Finds Hidden Mpox Infections May Drive Ongoing Spread

Mpox continues to circulate despite vaccination, and many cases show no known link to a symptomatic partner. The role of people without symptoms has remained uncertain, limiting clarity on how transmission persists.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.